For immunochemical detection of the SARS-CoV-2 nucleocapsid protein
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Nucleocapsid Protein Rabbit Monoclonal Antibody (Clone 0004)

Item No. 31801

Product Insert (PDF)
Technical Information
Synonyms
  • SARS-CoV-2 NP
  • SARS-CoV-2 Nucleoprotein
  • Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein
  • COVID-19 NP
  • COVID-19 Nucleoprotein
  • COVID-19 Nucleocapsid Protein
  • 2019-nCoV NP
  • 2019-nCoV Nucleoprotein
  • 2019-nCoV Nucleocapsid Protein
Immunogen
Recombinant SARS-CoV-2 nucleocapsid protein
Clone Designation
0004
MW
~47 kDa
100 µl of protein A-affinity purified monoclonal antibody
Storage Buffer
0.2 μm filtered solution in PBS
Host
Rabbit
Isotype
IgG
Applications
ELISA, WB
Cross Reactivity
(+) Nucleocapsid protein
Species Reactivity
(+) SARS-CoV-2(+) SARS-CoV-2 Omicron (B.1.1.529)(+) SARS-CoV-2 Omicron (BA.2)(+) SARS-CoV-2 Omicron XE (BA.1 x BA.2)(+) SARS-CoV-2 Omicron (BA.4)(+) SARS-CoV(+) MERS-CoV(-) HCoV-229E(-) HCoV-NL63(-) HCoV-HKU1(-) HCoV-OC43(-) Influenza A H1N1 (A/California/07/2009)(-) Influenza A H3N2 (A/Switzerland/9715293/2013)(-) Influenza A H2N2 (A/Ann Arbor/6/1960)(-) Influenza A H7N9 (A/Shanghai/2/2013)(-) Influenza B (B/Florida/4/2006)
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein is a viral protein encoded by the N gene in SARS-CoV-2 RNA.1 SARS-CoV-2 is a member of the Betacoronavirus genus of viruses and has 88% sequence identity with two bat-derived SARS-like CoVs.2 SARS-CoV-2 nucleocapsid protein is composed of an N-terminal domain (NTD) that binds RNA, a disordered linker region that contains regulatory phosphorylation sites, a C-terminal domain (CTD) that mediates dimerization, and a C-terminal tail.3 In a similar virus, SARS-CoV, the nucleocapsid protein packages the viral RNA into a helical ribonucleoprotein (RNP) complex that is a template for viral replication.4 The SARS-CoV nucleocapsid protein is integral for viral self-assembly and is involved in cell cycle regulation. The SARS-CoV-2 nucleocapsid protein gene sequence is greater than 90% similar to the SARS-CoV nucleocapsid protein, and it contains 27 T cell epitopes that are identical to SARS-CoV T cell epitopes.5 SARS-CoV-2 nucleocapsid protein inhibits the formation of stress granules, which sequester viral factors and are involved in the host antiviral response.6 SARS-CoV-2 is the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.7,8,9 Cayman’s SARS-CoV-2 Nucleocapsid Protein Rabbit Monoclonal Antibody (Clone 0004) can be used for ELISA and Western blot (WB) applications. This recombinant antibody recognizes nucleocapsid protein at 45.6 kDa from SARS-CoV-2, several SARS-CoV-2 Omicron subvariants, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et alFrom SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et alGenomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Zhang, B., Tian, J., Zhang, Q., et alComparing the nucleocapsid proteins of human coronaviruses: Structure, immunoregulation, vaccine, and targeted drug. Front. Mol. Biosci. 9, 761173 (2022).

    4. Chang, C.-K., Hou, M.-H., Chang, C.-F., et alThe SARS coronavirus nucleocapsid protein – Forms and functions. Antiviral Res. 103, 39-50 (2014).

    5. Ahmed, S.F., Quadeer, A.A., and McKay, M.R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12(3), E254 (2020).

    6. Zheng, Z.-Q., Wang, S.-Y., Xu, Z.-S., et alSARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication. Cell Discov. 7(1), 38 (2021).

    7. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et alNovel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    8. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et alIncidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    9. Yang, F., Shi, S., Zhu, J., et alAnalysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).